| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -3,069 | 1,388 | -26,829 | -34,721 |
| Depreciation and amortization | 771 | 728 | 451 | 885 |
| Amortization of debt discount | 277 | 614 | 414 | 859 |
| Change in fair value of derivatives | 9,416 | 1,177 | -3,332 | 2,004 |
| Change in fair value of share payable | 201 | -33 | -118 | -263 |
| Change in fair value of convertible notes | 5,235 | 19,559 | -15 | 6,089 |
| Loss from extinguishment of debt | -4,756 | -1,595 | -4,004 | -11,798 |
| Loss from issuance of debt | -738 | -2,292 | -1,611 | -773 |
| Inducement expense | 87 | NaN | NaN | NaN |
| Amortization of operating lease right-of-use asset | 76 | 73 | 70 | 130 |
| Stock-based compensation for services | 288 | 185 | 273 | 749 |
| Allowance for credit loss | 311 | NaN | NaN | NaN |
| Subtotal of non-cash charges | -7,548 | -15,216 | 10,288 | 7,364 |
| Prepaid expenses and other current assets | 2,276 | 448 | 500 | -111 |
| Other non-current assets | -2 | -2 | -10 | -3 |
| Accounts payable and accrued expenses | 886 | -1,103 | 1,321 | 7,534 |
| Related party accounts payable and accrued expenses | -364 | 551 | 1,825 | 3,564 |
| Lease liabilities | -140 | 62 | -8 | 39 |
| Net cash used in operating activities | -12,509 | -14,764 | -13,893 | -16,106 |
| Purchase of equipment and construction in progress | 129 | 905 | 202 | 397 |
| Loan receivable | NaN | 0 | 311 | NaN |
| Proceeds from issuance of notes payable, net | NaN | 5,000 | 0 | 7,000 |
| Net cash used in investing activities | -129 | -905 | -513 | -397 |
| Proceeds from issuance of common shares | 2,900 | 2,015 | 4,862 | 12,442 |
| Proceeds from exercise of warrants | 6 | 0 | 0 | 23 |
| Proceeds from issuance of convertible notes payable, net | 7,469 | 6,573 | 7,175 | 5,507 |
| Repayment of notes payable | NaN | 0 | 4 | 255 |
| Repayment of convertible notes payable | 500 | 0 | 475 | 536 |
| Payment of purchase consideration to related party | 666 | NaN | NaN | NaN |
| Net cash provided by financing activities | 9,209 | 13,588 | 11,558 | 24,181 |
| Effect of exchange rate changes on cash and cash equivalents | 2,175 | 561 | 3,092 | -5,537 |
| Net (decrease) increase in cash and cash equivalents | -1,254 | -1,520 | 244 | 2,141 |
| Cash and cash equivalents, beginning of the period | 3,040 | 4,560 | 2,175 | NaN |
| Cash and cash equivalents, end of the period | 1,786 | 3,040 | 4,560 | NaN |
NORTHWEST BIOTHERAPEUTICS INC (NWBO)
NORTHWEST BIOTHERAPEUTICS INC (NWBO)